NEW YORK and RA’ANANA, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment of Stuart Holden, M.D., to its Board of Directors and the addition of Mark Schoenberg, M.D., as Medical Director.
Dr. Stuart Holden is a co-founder of ProQuest Investments, a healthcare-focused venture capital firm, and a Chairman of its Scientific Advisory Board since the firm was established in 1998. He has been a practicing urologist for the past 40 years and has worked at the forefront of drug development pioneering new treatments for prostate and urologic cancers. He is a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology at the UCLA David Geffen School of Medicine, and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation, which is the world’s largest prostate cancer research funding organization; he has held this position since the foundation’s inception in 1993. Dr. Holden received a B.A. from the University of Wisconsin-Madison and holds an M.D. from Weill Cornell Medical College. Dr. Holden also completed a fellowship in Urologic oncology and developmental genetics at MSKCC.
Dr. Mark Schoenberg is a recognized leader in bladder cancer clinical care and research. Dr. Schoenberg served as the Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urology at Johns Hopkins Medical School. His clinical practice and research have focused on the care of patients with all forms of bladder cancer. He is the past Chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, a contributor to Campbell's Urology and a seminars editor of the journal Urologic Oncology. Dr. Schoenberg received his medical degree from the University of Texas Health Sciences Center and completed his residency in general surgery and urology at the Hospital of the University of Pennsylvania. Dr. Schoenberg also completed a fellowship in Urologic Oncology at Johns Hopkins under the auspices of The American Cancer Society.
Ron Bentsur, Urogen Pharma’s Chief Executive Officer, commented, “We are excited to announce the addition of two renowned urologists to our leadership team. Both Stuart and Mark are practicing physicians and esteemed leaders in the field of urology. We believe that their addition to our team is further validation of our science and novel approach to addressing some of the most pressing needs in uro-oncology today.”
About UroGen Pharma
UroGen Pharma is a clinical stage biopharmaceutical company focused on the development of novel, locally administered therapies for urological pathologies, including product candidates in uro-oncology that utilize novel chemoablation and immunomodulation approaches. UroGen has three uro-oncology product candidates in various stages of clinical development, as well as several preclinical product candidates. In addition, UroGen is developing a clinical-stage product candidate for the treatment of overactive bladder and interstitial cystitis and has recently established a preclinical collaboration with a strategic partner for the development of this compound for the treatment of overactive bladder. Please click on the following link to learn more: www.urogen.com
Forward Looking Statements
This press release contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen Pharma’s anticipated results of the operations and financial position, business strategy and operating plans. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of preclinical studies and clinical trials conducted by or on behalf of UroGen Pharma, including with respect to the efficacy and safety of its product candidates; UroGen Pharma’s ability to obtain and maintain regulatory approval of its product candidates, and the labeling for any approved products; the scope, progress, expansion and costs of developing and commercializing UroGen Pharma’s product candidates; UroGen Pharma’s ability to obtain and maintain intellectual property protection for its product candidates; UroGen Pharma’s anticipated growth strategies; UroGen Pharma’s expectations regarding competition; the anticipated trends and challenges in UroGen Pharma’s business and the markets in which it operates; UroGen Pharma’s ability to attract or retain key management and personnel; the size and growth of the potential markets for UroGen Pharma’s product candidates and its ability to serve those markets; the rate and degree of market acceptance of UroGen Pharma’s product candidates vis-à-vis alternative therapies; UroGen Pharma’s expectations regarding regulatory requirements; developments in applicable regulatory regimes; and the manner in which UroGen Pharma intends to use its cash resources and the sufficiency thereof. Moreover, UroGen Pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for UroGen Pharma’s management to predict all risks, nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements contained herein. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.
Source: UroGen Pharma